PTPN11 and acute myeloid leukemia: As pediatric and adult AML have distinct mutational profiles, the ELN2022 adverse risk mutations developed for adult patients were rare and not significantly enriched among the Stem11-high pediatric patients, while the Stem11-high pediatric patients had significantly higher frequencies of PTPN11 and WT1 mutations (Figure S11B).